ScholarIQanswers from OpenAlex & ORCID
Eric Assénat
ResearcherPublications, citations & collaboration network
Eric Assénat is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Eric Assénat have?
ScholarIQindexed works
Eric Assénat has 330 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Eric Assénat have?
ScholarIQcitation count
Eric Assénat has 23,113 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Eric Assénat?
ScholarIQh-index
Eric Assénat has an h-index of 53 in OpenAlex.
What is the i10-index of Eric Assénat?
ScholarIQi10-index
Eric Assénat has an i10-index of 143 in OpenAlex.
What is the ORCID of Eric Assénat?
ScholarIQorcid
The ORCID for Eric Assénat is on the source record.
What is the OpenAlex record for Eric Assénat?
ScholarIQopenalex
The OpenAlex for Eric Assénat is on the source record.
What are the most-cited papers on Eric Assénat?
ScholarIQmost cited works
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Eric Assénat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Dominique Farge, Corinne Frère, Jean M. Connors, Cihan Ay, Alok A. Khorana, Andrés J. Muñoz Martín, Benjamin Brenner, Ajay K. Kakkar, Hanadi Rafii, Susan Solymoss, Dialina Brilhante, Manuel Monréal, Henri Bounameaux, Ingrid Pabinger, James D. Douketis, Walter Ageno, Fernando Ajauro, Kamal R. Al-Aboudi, Thierry Alcindor, Thierry André, Pantep Angchaisuksiri, Darko Antić, Juan I. Arcelus, Eric Assénat, Kenneth A. Bauer, Ali Bazarbachii, Ilham Benzidia, Jan Beyer‐Westendorf, Viktoria Bitsadze, Dorit Blickstein, Mark Blostein, Isabel Bogalho, Barbara Bournet, Patricia Casais, Alain Carpentier, Gabriela Cesarman‐Maus, Joydeep Chakbrabartty, Hugo Clemente, J. Connault, Ludovic Doucet, C. Durant, Joseph Emmerich, Anna Falanga, Clemens Feistritzer, Carme Font, Charles W. Francis, Enrique Gallardo, Thomas Gary, Jean‐Christophe Gris, Cecilia Guillermo, A. Hij, Russel Hull, Takayuki Ikezoe, Luis Jara‐Palomares, Nigel S. Key, Jamilya Khrizroeva, Maral Koolian, Florian Länger, C. Le Hello, Ramón Lecumberri, Lai Heng Lee, Howard A. Liebman, Luisa Lopes Dos Santos, Duarte Machado, Isabelle Madelaine, А. D. Makatsariya, Mario Mandalà, Anthony Marayevas, Zora Marjanovic, Christine Marosi, Ellis Martin, Luis Meillón, E. Messas, António Moreira, Ahmet Muzaffer Demir, Arlette Ndour, Michel N'Guessan, Remedios Otero, Vanessa Pachón Olmos, Ana Pais, Florian Posch, Matthias Preusser, H. Riess, Marc Righini, Cynthia Rothschild, André Roussin, José Antonio Rueda-Camino, Pedro Ruiz‐Artacho, Sanjith Saseedharan, Ali Shamseddine, Gerald A. Soff, Hans Stricker, Vicky Tagalakis, Alì Taher, Toussaint Toutou, Javier Trujillo‐Santos, Stéphane Villiers, Raymond Wong, Norizaku Yamada
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Bruno Sangro, Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, Shukui Qin, Zhenggang Ren, Stephen L. Chan, Yasuaki Arai, Jeong Heo, Anh Mai, Jose Escobar, Yamil Alonso Lopez Chuken, Jung-Hwan Yoon, Won Young Tak, Valeriy V Breder, Tanita Suttichaimongkol, Mohamed Bouattour, Shi-Ming Lin, Jean-Marie Peron, Quang T Nguyen, Lünan Yan, Chang-Fang Chiu, Florinda A Santos, Anil Veluvolu, Satheesh Chiradoni Thungappa, Marco Matos, Magdalena Żotkiewicz, Stephanie I. Udoye, John F. Kurland, G. Cohen, Riccardo Lencioni, Kathia Cristina Abdalla, Manon Allaire, Gustavo R. Alves, Luís Carlos Moreira Antunes, Eric Assénat, Sérgio Jobim Azevedo, Rafael Barreto, Muhammad Shaalan Beg, Glaucio Bertollo, Jean‐Frédéric Blanc, Mohamed Bouattour, Rakesh Reddy Boya, Valery Breder, Jean–Pierre Bronowicki, Manoch Buranachokphaisan, Adam M. Burgoyne, Stephen L. Chan, Ting‐Tsung Chang, Yee Chao, Eric Chen, Xiaoming Chen, Chang-Fang Chiu, Minsig Choi, SUNGHEE CHOI, Natalie G. Coburn, Luis Contreras, Farshid Dayyani, Thomas Decaens, Arunee Dechaphunkul, Maria del Consuelo Diaz, Anouk Dev, Jamille Dutra, Melissa Eastgate, Jose Escobar, Bassam Estfan, Vittorio Ferrari, Anne-Claire Frin, Sandip Ganguly, Ranga Raman Ganta, Shanzhi Gu, Yabing Guo, Atsushi Hagihara, Jeong Heo, Chih‐Hung Hsu, Jimmy Hwang, Yoshitaka Inaba, Shikha Jain, D. Jonker, Shruti Kate, Shruti Kate, Naoya Kato, Tomokazu Kawaoka, Kwong‐Ming Kee, Seung Up Kim, Kiyohide Kioka, Hironori Koga, Masatoshi Kudo, Hidekatsu Kuroda, Phuong Uyen Le, Han-chu Lee, Joon Hyeok Lee, Teng-Yu Lee, Dongliang Li, Hailiang Li, Wei Li, Xiao Li, Cheng-Yao Lin, Shi-Ming Lin, Yamil Lopez
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
Barbara Bournet, Fabrice Muscari, Camille Buscail, Eric Assénat, Marc Barthet, Pascal Hammel, Janick Sèlves, Rosine Guimbaud, Pierre Cordelier, Louis Buscail